Performance of phase-I dose finding designs with and without a run-in intra-patient dose escalation stage.
Saved in:
| Title: | Performance of phase-I dose finding designs with and without a run-in intra-patient dose escalation stage. |
|---|---|
| Authors: | Labrenz J; NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany.; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany., Edelmann D; NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany.; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany., Heitmann JS; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany., Salih HR; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany., Kopp-Schneider A; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany., Schlenk RF; NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany.; Department of Internal Medicine V and Internal Medicine VI, Heidelberg University Hospital, Heidelberg, Germany. |
| Source: | Pharmaceutical statistics [Pharm Stat] 2023 Mar; Vol. 22 (2), pp. 236-247. Date of Electronic Publication: 2022 Oct 25. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley Country of Publication: England NLM ID: 101201192 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1539-1612 (Electronic) Linking ISSN: 15391604 NLM ISO Abbreviation: Pharm Stat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1539-1612 |
|---|---|
| DOI: | 10.1002/pst.2268 |
